Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' resubmission of the atrial fibrillation medication Multaq is expected to include data from the ongoing ATHENA trial.
You may also be interested in...
FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review
FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.
FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review
FDA asks Cardiovascular and Renal Drugs advisory committee to compare Sanofi’s negative dronedarone trial to its new pivotal trial.
Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron
In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews